Access DX Laboratory: Purchased Orders and Unbundled Genetic Tests

The Access DX Laboratory settlement combined $36.4 million in civil agreements by the Houston laboratory, its former CEO and a Florida businessman over alleged kickbacks and medically unnecessary genetic testing billed to Medicare and Medicaid. The government alleged that they bought both patient referrals and false doctors’ orders, and unbundled genetic-testing billing codes. The alleged scheme charged taxpayers for tests patients did not need.

The Department of Justice announced the combined settlements on July 30, 2026. Its allegations cover January 2018 through January 2020 and reach across the laboratory, marketers and telemedicine providers. The whistleblower who brought the civil case was the president of a marketing company hired to promote genetic testing to Medicare and Medicaid beneficiaries.

Purchased Telemedicine Orders Behind Genetic Claims

The government alleged that Access DX and the two individuals paid marketers kickbacks for genetic-testing patient referrals and paid telemedicine providers for false and fraudulent doctors’ orders. They then submitted, or caused others to submit, false genetic-testing claims. The alleged payments reached both the source of the patients and the source of the medical paperwork.

That ordering relationship matters because a laboratory test begins with a clinical decision. Under Medicare’s diagnostic-testing rules, the treating physician or qualified practitioner orders the test and keeps the medical-necessity documentation. The laboratory submitting the claim keeps the information it receives and documentation showing that its claim accurately reflects that information.

An order therefore connects different businesses and different records. The clinician’s record should explain the medical reason for the test. The laboratory’s requisition and billing records show what information arrived and what the laboratory charged for. In the Access DX allegations, the payment to the telemedicine provider is part of that connection: the government said the laboratory and the individuals paid for false orders.

For a marketer or laboratory employee, the useful knowledge may concern who arranged those orders, what the telemedicine provider was paid to supply, or how an order reached the laboratory. We connect that account with the referral terms and the resulting claims.

Unbundling Genetic Tests on the Claim

Unbundling turns a panel into separately billed components. The government expressly alleged that Access DX and the individuals unbundled genetic-testing billing codes, alongside the referral and false-order allegations.

The payment incentive is easier to see in the older laboratory business. In its 1998 report on hospital billing practices, the General Accounting Office explained that automated testing could perform several tests on one blood sample and that a profile generally paid less than the same tests billed separately. Breaking the profile into individual codes could produce an overpayment for the same laboratory work.

Genetic testing also carries substantial payment weight. In the HHS Office of Inspector General’s analysis of Medicare Part B laboratory spending, genetic tests, including human and pathogen testing, represented 5% of paid tests in 2024 but 43% of laboratory spending.

For a laboratory insider, the requisition, the test performed and the claim tell different parts of the transaction. The requisition shows the selection. The testing record shows the work. The claim shows how the laboratory represented that work for payment. Reading them together makes the unbundling question concrete.

What the Ordering Physician Selected

Laboratory profiles can package several tests behind a single selection, making the contents of the order as important as the presence of an order. A physician selecting a profile needs to know what the laboratory will run and how it will bill those tests.

The Laboratory Medicine article Model Plan Helps Laboratories Fight Fraud, published in 1997, described the Office of Inspector General’s recommendations for explaining profile components and billing to ordering physicians. On customized profiles, it made the responsibility concrete:

The acknowledgment puts the physician’s understanding of payment rules on paper. The article also described monitoring standing orders for continued validity and putting space on requisitions for the diagnosis supporting each test.

The practical question runs through the laboratory-fraud cases: what did the clinician select for this patient, and what did that selection become inside the laboratory? A form can make a broad menu easy to order while the claim presents each test as a separate service.

Separate Settlements and an Earlier Integrity Agreement

Access DX entered a civil settlement and a five-year Corporate Integrity Agreement with the HHS Office of Inspector General. The agency’s entry for Access DX dates the agreement’s start to July 26, 2023 and lists $30,100,000 for the laboratory’s settlement. The larger combined total announced later also covered the former CEO and the Florida businessman.

The company’s integrity agreement reaches back into the business relationships behind the claims. The Office of Inspector General’s entry identifies reviews of claims and of arrangements with referral sources. That pairing addresses the central connection in the case: how the laboratory acquired business and what it billed afterward.

Other Cases Connect the Order to the Payment

Other laboratory cases show how the order and the billing record can diverge. Each offers a different comparison for someone who knows the forms, referral relationships or claims inside a laboratory.

In the 2015 Millennium Health settlement, $10 million addressed genetic-testing allegations. The government’s broader case alleged medically unnecessary testing and free items supplied to physicians who agreed to refer expensive laboratory work. The referral relationship and the clinical need for the tests appeared in the same case.

In its 2023 civil settlement, Genotox Laboratories admitted offering custom profiles that let providers preselect tests for all or nearly all their patients. Genotox then performed and billed those tests, generally at the highest reimbursement categories. The choice made on a form became repeated testing across patients.

The 2019 GenomeDX Biosciences settlement concerned allegations that the company billed for its Decipher prostate cancer test without the patient risk factors supporting it. The whistleblowers’ complaint alleged that physicians were instructed to pre-sign blank medical-necessity certificates, which the company then completed for individual claims:

That allegation puts the order problem in plain view. The signature was allegedly already on the form before the patient’s name was added. Someone handling the forms could see a sequence that the completed certificate concealed.

The Marketing Insider and the Whistleblower Reward

The Access DX whistleblower came from the marketing side of the business. The president of a Massachusetts marketing company brought the qui tam case whose claims the civil settlements resolved, and the settlements provide for a $7.2 million whistleblower share.

That role matters to an insider considering what they know. A marketer may know the referral terms and compensation. A billing employee may see the genetic codes and claims. A laboratory or compliance employee may see how orders were accepted and referral arrangements reviewed. Those views can connect the commercial decision to the claim sent to a government health care program.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our whistleblower experts start with the part of the laboratory business you know and work with you to build the strongest case it can support.

You Saw How the Orders Reached the Lab

If you know who paid for the referrals, who supplied the telemedicine orders or how the genetic tests were billed, talk with our whistleblower experts about the laboratory business you saw. We build the case with you, bring in healthcare whistleblower lawyers who know laboratory kickbacks and genetic-testing claims, and stay beside you through the pursuit of a recovery.